AVIV ITZHAKI: Open Payments
NPI 1891938593 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,269 in 50 payments from 15 companies in 2025. Trend: 2023 $617 · 2024 $813 · 2025 $1,269
Food & beverage: $1,269
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $228 |
| Otsuka America Pharmaceutical, Inc. | 8 | $214 |
| E.R. Squibb & Sons, L.L.C. | 5 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $124 |
| Neurocrine BioSciences, Inc. | 5 | $117 |
| Janssen Pharmaceuticals, Inc | 4 | $95 |
| Almatica Pharma LLC | 3 | $57 |
| ABBVIE INC. | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Lundbeck LLC | 2 | $50 |
Products named: ARISTADA, REXULTI, COBENFY, CAPLYTA, INGREZZA, LOREEV XR, VRAYLAR, TRINTELLIX.
Industry payments across NV — which companies pay providers there.
